Solara Active Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 26 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.9K Cr

The company aims for at least 3-4 quarters of growth to demonstrate a strong turnaround. Solara aims for **sustainable, scalable, and profitable growth** moving forward, focusing on 3-4 quarters of consistent growth to demonstrate a turnaround.

From Solara Active's Q2 FY26 earnings-call transcript · updated 26 Aug 2026.

Price

₹629

Market Cap

₹2.9K Cr

P/E Ratio

690.5

How does Solara Active rank in Pharmaceuticals & Biotechnology?

Compare Solara Active against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Solara Active — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹387 Cr, net profit ₹10 Cr.

Full financials →

📊 Revenue & Sales Performance

→The company aims for at least 3-4 quarters of growth to demonstrate a strong turnaround.
→They have an outlook of approximately 10% sales/revenue growth.
→Growth will come from expanding into new markets beyond the US, Europe, and Japan, including Latin America, South Korea, and the Middle East.
→Current facility capacity utilization is about 70%, with capacity available to serve new customers.
→Incremental sales will be focused on higher-margin and value-added product lines such as ibuprofen derivatives.
→The R&D pipeline is being developed, but new product approvals and launches are expected over a 2-3 year time horizon.
→Short-term growth will be supported by cost reduction initiatives and debottlenecking of existing capacity.
→The business believes that 10% growth rate is sustainable and there is potential to exceed this over the next 2-3 years.

📈 Profitability & Margins

→Solara aims for **sustainable, scalable, and profitable growth** moving forward, focusing on 3-4 quarters of consistent growth to demonstrate a turnaround.
→The company targets **10% revenue growth** and **15%-20% EBITDA growth** over the financial year, based on FY '25 as the base.
→Margins are expected to improve with a focus on **high gross margin products**, operational cost reductions, and capacity debottlenecking.
→New product launches, especially in value-added segments like ibuprofen derivatives, are expected over the next 2-3 years, although they have a gestation period.
→Short-term disruptions (like the recent shutdown) are seen as transitory; the underlying fundamentals remain strong with a healthy gross margin ~51%+.
→Debt reduction and liquidity improvements are prioritized, which will support profitability in the medium term.
→Management is not providing specific capex numbers due to liquidity focus but is making small, strategic investments for capacity expansion.

See what Solara Active said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→The company is not planning any big capital investments currently due to liquidity constraints.
→Capex is focused on small, bite-sized investments primarily aimed at debottlenecking existing capacity.
→Ongoing capex projects are designed to be executed on time to increase capacity and support future growth.
→No specific capex figures for upcoming periods were provided; investment plans will depend on how existing projects progress.
→Regarding the new CRAMs and polymer chemical business (expected after demerger), no immediate investment from Solara is anticipated as this business has a longer gestation period.
→The management remains cautious and prudent with capital allocation, focusing on profitable growth and capacity optimization rather than large-scale expansion.

💰 Fundraising & Capital Structure

→There is no specific mention of any imminent new fundraising through debt or equity.
→The company is focused on reducing existing debt, having reduced debt by about INR153 crores in H1 FY '26 and aiming to reduce it further to around INR446 crores by Q1 FY '27.
→Management emphasizes cautious, small bite-sized capex investments primarily for debottlenecking capacity, considering current liquidity constraints.
→Regarding the demerger, there is a transfer of INR200 crores debt planned to the new entity, but no immediate additional investment in that business is anticipated due to its longer gestation period.
→The company is mindful of its liquidity situation and is actively managing cost and working capital but has not disclosed plans for fresh equity or debt raising in the near term.

See what Solara Active said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→Solara Active Pharma Sciences has experienced some short-term disruptions impacting production (Page 12).
→Despite a 4-week operational shutdown, management indicated the lost sales orders have not been lost permanently and will be fulfilled in the next two quarters or by Q4 if delayed (Page 12).
→The company expects to service deferred revenue/orders by utilizing available capacity in coming quarters, aiming to catch up on production backlog (Page 12).
→Facility utilization stands around 70%, with available capacity to cater to new and existing markets (Page 13).
→They are optimistic about strengthening order books by expanding into new attractive global markets beyond U.S., Europe, and Japan (Page 13).
→Overall, the order book visibility is improving with a focus on sustainable and profitable growth, although some temporary one-offs have affected near-term order fulfillment (Page 15).

Key Metrics

What Solara Active's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Alivus Life Sciences Ltd (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
Sun Pharma.Inds. (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
Zydus Lifesciences Ltd (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…
Sudeep Pharma Ltd (Q2 FY26)
NSS acquisition to drive European expansion with a focus on PAN-Europe growth; infant nutrition (70-75% of NSS revenue) is a key area. Key concall takeaways…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Solara Active Q2 FY26 results?

What is Solara Active share price analysis?

Solara Active currently shows a neutral. The stock trades at a P/E of 690.5 with a market cap of ₹2,948 Cr. Investors should review the full earnings analysis for detailed insights.

Is Solara Active planning capital expenditure?

The company is not planning any big capital investments currently due to liquidity constraints.

Keep Solara Active on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.